Therapy targeting hypoxia-inducible factor-1 (HIF-1) to reverse the hypoxia-related drug resistance has received much interest. Despite a close interaction between HIF-1 and p53 and that p53 mutation is seen in 450% of tumors, whether HIF-1 silencing by targeted therapy depends on tumor p53 status remains unknown. Two isogenic fibrosarcoma cells HT1080 (wild-type p53) and HT1080-6TG (mutant p53) were transduced with HIF-1a-specific RNAi lentiviral vectors and selected with blasticidin. Real-time PCR and western blot analysis of HIF-1a mRNA and protein respectively validated the silencing effects. Cells were first preconditioned under hypoxia (0.5% O 2 ) for 4 h and then co-treated with cisplatin for another 24 h. MTT was used for assessment of chemosensitivity to cisplatin. Moreover, annexin V and propidium iodide staining was detected on flow cytometry for analysis of cisplatin-induced apoptosis. Furthermore, changes of some Bcl-2 family members were detected on western blotting. Exposure to hypoxia significantly increased resistance to cisplatin than exposure to normoxia. HIF-1a knockdown could reverse hypoxia-related resistance to cisplatin and apoptotic resistance only in HT1080 cells, but had little effect on HT1080-6TG cells. With HIF-1a knockdown, Bid expression was higher in HT1080 than in HT1080-6TG under hypoxia. In summary, HIF-1 targeted therapy to reverse hypoxia-related cisplatin resistance depends on normal p53 status. Changes of Bid expression levels under hypoxia might contribute in part to the differential response to HIF-1a silencing in cells with different p53 status.
Introduction
Hypoxia-a reduction in the normal level of tissue oxygen tension, including acute and chronic hypoxia-is the most important and prevailing character of microenvironments in solid tumors. The condition results in part from unlimited growth of tumor cells, insufficient blood supply and angiodysplasia. A large pool of evidence has shown that hypoxia is closely related to tumor resistance to radiation and drugs, as well as poor prognosis. As the most important transcription factor, hypoxia inducible factor-1 (HIF-1) plays important roles in the expression of many genes associated with neoangiogenesis, glycolysis and antiapoptosis, which allow the cancer cells to survive and even proliferate under hypoxia. Therefore, HIF-1 has been a molecular target of therapy resistance. [1] [2] [3] [4] Although HIF-1a level is good indicator of poor outcome in clinical data, evidence of the role of HIF-1a in hypoxia-related radiation and drug resistance is inconsistent because of different oxygen concentration and cell lines used in experiments.
5-10 HIF-1 knockdownmediated radiation or drug sensitization under normoxia produced negative results in some studies since HIF-1 was expected to play minor roles in the presence of O 2 . Cells with normal or suppressed HIF-1 status were not indicated as the major part of therapy barrier under normoxia. Furthermore, different p53 status of cell lines might also contribute to the inconsistent results.
Given the close cross talk between the microenvironment and tumor genes, especially the interaction between HIF-1 and tumor p53, [11] [12] [13] [14] therapy targeted toward HIF-1 is hypothesized to depend in part on p53 functional status. Most studies of cross talk between HIF-1 and p53 focused on the direct interaction between proteins, regulation of the cell cycle, apoptosis and the expression of downstream genes. 11, 12, [15] [16] [17] [18] [19] [20] p53 mutation was associated with a malignant phenotype, and HIF-1 could enhance such effects. At least part of the proapoptotic action of HIF-1 was realized by inhibition of p53 degradation. However, wild-type p53 could inhibit the transcriptional activity of HIF-1 and expression of downstream genes. Regardless, how HIF-1 cooperates with p53 in hypoxia-related radiation and drug resistance remains poorly understood. Only one study has reported the in vitro effect of direct interaction of HIF-1 with normal or defective p53 on radiation sensitivity in human prostate PC-3 cells; instead of radiation sensitization, HIF-1 inhibition resulted in even greater radiation resistance. 21 HIF-1a is seen in 70% tumor primary lesions and metastasis, 22 and p53 mutation in 450% neoplasms, 23 the interaction of HIF-1 with the wild-type or mutant p53 would be common in tumors and also be of great prognostic and therapeutic value. HIF-1 expression, together with p53 mutation, was suggested to indicate the worst prognosis in both gastric cancer and superficial urothelial bladder carcinoma, 24, 25 which warrants further research in other cancer patients.
We aimed to explore the effects of HIF-1 knockdown on hypoxia-related resistance to the anticancer drug cisplatin and their dependence on p53 status in fibrosarcoma cells using lentivirus-packed short-hairpin RNA (shRNA) as well as the underlying molecular mechanisms.
Materials and methods
Cell lines and cell culture HT1080 and HT1080-6TG cells were kindly offered by Dr Eric J Stanbridge (Department of Microbiology and Molecular Genetics, University of California, Irvine, CA) and maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco, Carlsbad, CA) containing 10% heatinactivated fetal bovine serum (Gibco) at 37 1C in a humidified atmosphere of 5% CO 2 .
Production of lentiviral vector
With use of BLOCK-iT Lentiviral RNAi Expression System (catalog no. K4944-00; Invitrogen, Carlsbad, CA), we constructed a transfer plasmid pLenti6-HIF-1 harboring human HIF-1a shRNA-expressing cassette and a nonspecific control plasmid following the manufacturer's instructions. The target sequence was GATACAAG TAGCCTCTTTG, selected according to the HIF1mRNA sequence (GenBank: BC012527) and previously tested to be efficacious to induce a strong RNAi. 4 Lentiviral vector supernatant pseudotyped with the vesicular stomatitis virus glycoproteins was produced by four-plasmid co-transfection in the HEK 293FT transient system. An amount of 9 mg of the ViralPowerTM Packaging Mix and 3 mg of pLenti6-HIF-1a or control plasmid (12 mg total) were used to co-transfect 6 Â 10 6 HEK 293FTcells with 36 ml of Lipofectamine 2000 in a 10-cm cell culture dish. The medium containing DNA-LF 2000 complexes was replaced with complete culture medium containing sodium pyruvate. Viral supernatant was harvested 48 and 72 h after transfection and filtered through a 0.45-mm cellulose acetate filter, then ultracentrifuged at 25 000 g at 4 1C for 2 h. The viral pellets were resuspended in serum-free DMEM, divided into aliquots and frozen at À70 1C.
Construction of stable HIF-1a-silenced cells HT1080 and HT1080-6TG cells were transduced with specific or control lentiviral vectors at one multiplicity of infection and were selected for stable integrants by culture in complete medium containing blasticidin (6 mg ml
À1
). After 10-12 days of selection, the mock well contained no viable cells, and the transduced cells contained discrete blasticidin-resistant colonies, named as HT1080/HIF-1a(À), HT1080/NS (in brief, named HT1080 below), HT1080-6TG/HIF-1a(À) and HT1080-6TG/NS (in brief, named HT1080-6TG below). Cells were used after 10-20 passages.
Exposure to hypoxia and cisplatin treatment Cells were first preconditioned under hypoxia (0.5% O 2 ) for 4 h, then co-treated with cisplatin (Sigma, St Louis, MO) at various concentrations for another 24 h in a humidified airtight O 2 -control incubator (Galaxy R, RS Biotech, UK) set at 37 1C in 0.5% O 2 and 5% CO 2 . At the same time, normoxia cells were placed at 37 1C in a 21% O 2 , 5% CO 2 incubator (BBD6220, Heraeus, Hanau, Germany).
MTT cell viability assay
Cells were seeded in 96-well plates overnight at 2 Â 10 4 per vial. Following exposure to 21 or 0.5% O 2 for 4 h, they were exposed to various concentrations of cisplatin for a further 24 h. Subsequently, 10 ml MTT (5 mg ml À1 in phosphate-buffered saline (PBS)) was added to each well for 4 h at 37 1C, then the formazan crystals were solubilized with 100 ml of 10% sodium dodecyl sulfate in 0.01 M HCl for 24 h. Absorbance at 550 nm relative to a reference wavelength of 630 nm was determined with use of a microplate reader (Bio-Rad 680; Bio-Rad, Hercules, CA). Absorbance values were expressed as percentages relative to untreated controls, and concentrations resulting in 50% inhibition of cell growth (IC 50 values) were calculated.
Protein western blot analysis After exposure to hypoxia for 24 h, cells were washed once with pre-cold PBS quickly and homogenized in extraction buffer containing 0.15 M NaCl, 50 mM Tris-HCl (pH 7.4), 5 mM EDTA (pH 8.0), 2 mM, 0.5% Triton-100, 5 mM dithiothreitol, 0.2 mM phenylmethylsulphonylfluoride and 4 mg ml À1 aprotinin. The lysates were incubated on ice for 4 h, then centrifuged at 12 000 g for 20 min at 4 1C. The supernatant was collected, and total cellular protein concentration was determined by the Bradford method. For immunoblot assays, 100 mg of protein samples were fractionated by 8% (HIF-1a, p53 and p53-ser15) or 15% (Bcl-2, Bid and Bax) resolving SDS-polyacrylamide gel electrophoresis (PAGE) according to the protein molecular weight. Then protein was electroblotted onto polyvinylidene fluoride membrane by use of an electronic Bio-Rad transfer apparatus. The membranes were blocked overnight at room temperature in 1 Â Tris-buffered saline (TBS)-0.05% Tween-20 (TBS-T) containing 5% dry milk powder. Blots were subsequently incubated for 4 h in 1% TBS-T buffer containing the following antibodies to different proteins: 1 mg ml À1 mouse anti-human HIF-1a (BD Biosciences, San Jose, CA), 2 mg ml À1 rabbit anti-human p53(ser15) antibody (Cell Signaling Technology, Beverly, MA), 5 mg ml À1 rabbit anti-human Bcl-2 and Bid (Cell Signaling Technology), 10 mg ml À1 mouse anti-human p53 and Bax antibody (Santa Cruz Biotechnology, Santa Cruz, CA ) and 2 mg ml À1 mouse anti-human actin (BibVision, Palo Alto, CA). Then the membranes were washed three times for a total of 30 min with TBS-T, then incubated for 1 h with horseradish peroxidase-labeled rabbit anti-mouse or goat anti-rabbit immunoglobulin G secondary antibody (1:1000; Amersham Biosciences, Buckinghamshire, UK). The amount of each protein sample was controlled by actin. After extensive washing with TBS-T for three times and TBS twice, the immunocomplexes on the membranes underwent reaction with ECLplus reagent (Amersham Biosciences) for 1 min and were exposed onto Kodak Imaging film. Radiographs were scanned and analyzed by use of Multi-image light cabinet and software (Alpha Innotech Corporation, San Leandro, CA). Results were normalized against b-actin bands and expressed as relative to control cells incubated in 21% O 2 .
RNA preparation and real-time RT-PCR analysis
Total RNA was isolated from culture cells by use of Trizol reagent (Invitrogen). One-Step SYBR RT-PCR Kit (TaKaRa, Shiga, Japan) was used for HIF-1a analysis, with actin used as an internal control. Primers for HIF-1a were as follows: forward primer 5 0 -CTG AGG TTG GTT ACT GTT GGT ATC-3 0 , reverse primer 5 0 -AGT GTA CCC TAA CTA GCC GAG GAA-3 0 . The actin primers were forward primer 5 0 -CAA CAC CCC AGC CAT GTA CGT TGC TAT-3 0 , reverse primer 5 0 -GCG AGA AGA TGA CCC AGA TCA-3 0 . Reactions were performed in a volume of 25 ml in triplicate for each sample according to the protocol. Each 25-ml reaction was composed of 2 Â one-step buffer 12.5 ml, TaKaRa Ex Taq HS (5 U ml À1 ) 0.5 ml, M-MLV RTase (200 U ml À1 ) 0.25 ml, RNase inhibitor (40 U ml À1 ) 0.5 ml, PCR F-P (10 mM) 0.5 ml, PCR R-P (10 mM) 0.5 ml, total RNA (100 ng) 2 ml, RNase-free water 8.25 ml and Rox reference dye 0.5 ml. Amplifications were performed in an ABI Prism 7000 Sequence Analyzer (Applied Biosystems, Foster City, CA) using the following cycle program: 42 1C for 15 min, 95 1C for 2 min; 95 1C for 5 s, 60 1C for 30 s, 40 cycles. The relative level of HIF-1a gene was calculated by comparing threshold cycle (C t ) values of samples to that of the reference. All data were normalized to the standard internal actin. Accordingly, DC t ¼ C t HIF-1a-C t actin, and DDC t ¼ DC t (transduced cells)ÀDC t (parental cells). The relative gene expression in a particular sample was given by the following: 2 ÀDDC t .
Annexin V assay of apoptosis Following 24-h exposure to hypoxia or normoxia or cotreatment with cisplatin (20 mM), cells were collected by trypsinization and washed with pre-cold PBS twice, resuspended in 500 ml annexin V-binding buffer with 1 Â 10 6 cells ml
À1
. An amount of 5 ml propidium iodide and 5 ml of annexin V-FITC (BD Pharmingen, San Diego, CA) were added and incubated for 15 min at room temperature in the dark. Fluorescence was measured on a flow cytometer (Becton Dickinson, San Jose, CA) and processed with Cell Quest software for analysis.
Statistical analysis and calculations
The oxygen enhancement ratio (OER) was termed as the ratio of anticancer drug doses under hypoxia to normoxia to achieve the same biologic effect and calculated as IC 50 (hypoxia)/IC 50 (normoxia). Student's t-test was performed with use of SPSS 11.5 to compare doubling time, IC 50 and OER among groups.
Results

Downregulation of HIF-1a by lentivirus-mediated HIF-1a shRNA
We previously described the lentivirus-mediated HIF-1a shRNA to be effective in the HIF-1a gene silence of A549 and SPCA-1 cells. 4 Similar results were obtained with the two isogenic cell lines HT1080 and HT1080-6TG. HIF-1a mRNA level decreased by 86.7 and 84.4%, respectively, under normoxia, but decreased by 91.6 and 97.3% under hypoxia.
To further confirm our finding of mRNA expression, protein levels of HIF-1a were measured. Under normoxia, HIF-1a was at a very low level in both parental cells and HIF-1a-silenced cells. Under 24-h hypoxia (0.5% O 2 ), HIF-1a protein was greatly accumulated in parental cells but barely in gene-silenced cells (Figure 1 ). HIF-1a protein expression decreased by 84.7 and 96.2% in HT1080/HIF-1a (À) and HT1080-6TG/HIF-1a (À) cells, respectively, under hypoxia. The results confirmed that lentiviral vector-mediated RNAi could stably block the induction of HIF-1a under hypoxia. Hypoxia protected cells against cisplatin cytotoxicity and drug-induced apoptosis Exposure of cells to 0.5% O 2 significantly increased resistance to various concentrations of cisplatin as compared with cells incubated under normoxia (21% O 2 ; Po0.05). About 2.47-fold cisplatin was required for half-maximal cytotoxic effects under hypoxia than normoxia in HT1080 (Figure 2) . The cytoprotective effects of hypoxia in HT1080-6TG cells was much less than that in HT1080 cells; the OER was only 1.72, which suggested dependence of OER on p53 status in fibrosarcoma cells. In other words, wild-type p53 enhanced the hypoxia-induced resistance to anticancer drugs. Consistent with the above results, cisplatin-induced apoptosis was significantly attenuated under hypoxia in both isogenic cells (Figure 3) .
Inhibition of hypoxia-induced drug resistance by HIF-1a interference depended on p53 status
Given the close relation between HIF-1 and p53, we hypothesized that the cross talk between the two factors might play important roles in the delicate regulation of hypoxia-related drug resistance. To that end, we analyzed HIF-1-silenced cells for drug sensitivity under both normoxia and hypoxia. As expected, HIF-1 interference attenuated hypoxia-induced cisplatin resistance in HT1080 cells; the IC 50 of HT1080/HIF-1a (À) under hypoxia approximated the level under normoxia, with an OER of only 1.47 (Figure 2) . By contrast, HIF-1a knockdown failed to reverse the hypoxia-related resistance in HT1080-6TG cells. The OER of HT1080-6TG cells was similar to that of HT1080-6TG/HIF-1a (À) cells.
Similarly, HIF-1 silencing could reverse hypoxiainduced resistance to apoptosis in HT1080 cells, but had little effect in HT1080-6TG cells (Figure 3) , which indicated that the effects of HIF-1 silencing depended 
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Expression of Bcl-2 family members under hypoxia and their association with HIF-1a and p53
To explore the possible underlying mechanisms responsible for hypoxia-related drug resistance, Bcl-2 family proteins were examined (Figure 4 ). Bcl-2 protein was not changed under hypoxia in two types of fibrosarcoma cells and their HIF-1a-silenced counterparts; however, the other proapoptotic protein Bid was increased in level under hypoxia to different degrees. Of note, Bid level was increased much more in HT1080/HIF-1a (À) cells than in the parent cells after 24-h hypoxia. Bax showed a slight increase in HT1080/HIF-1a (À) cells than HT1080 cells under hypoxia. In contrast, Bid and Bax expression was less different between HT1080-6TG cells and corresponding HIF-1a-silenced cells.
Discussion
In this study, we demonstrated that hypoxia protected fibrosarcoma cells against the cytotoxicity and apoptosis induced by anticancer drug cisplatin. More importantly, HIF-1a interference could overcome such drug resistance under hypoxia and might be exploited for clinical use. However, HIF-1a gene silencing worked only in p53 wild-type cells, despite p53 mutation being well known to occur in more than half of the neoplasms. As far as we know, this is the first report to explore the effects of cross talk between HIF-1 and p53 in hypoxia-related drug resistance. Most previous studies focused on the interaction between HIF-1 and p53 in p53 þ / þ and p53À/À isogenic cell lines. Few have investigated on whether and how HIF-1 interacts with mutant p53. 16, 20 We used two isogenic fibrosarcoma cells containing wild-type and mutant p53 in this study. HT1080-6TG cells were defective in two sites of the DNA binding site and lost transcription activities. 26 As well, we chose cisplatin a widely used DNA-damaging anticancer agent in the clinic, which causes apoptosis which was closely related to p53 activation. 27, 28 Furthermore, mechanisms of cisplatin-induced resistance under hypoxia are mainly due to indirect effects, including cell cycle arrest and DNA repair, not the O 2 itself. 29 Much evidence has shown that hypoxia is closely associated with tumor resistance to anticancer drugs, and many factors contribute to the mechanisms. 29 Both direct and indirect factors of hypoxia account for drug resistance. Since HIF-1 is one of the major regulators of adaptive response to hypoxia, targeting HIF-1 to reverse Effects of lentivirus-mediated HIF-1a knockdown J Hao et al the hypoxia-related drug resistance has received much interest. However, the roles HIF-1a plays in hypoxiarelated drug resistance are still inconclusive. 6, 10, [30] [31] [32] [33] Moreover, how HIF-1 cooperates with p53 to determine drug sensitivity remains poorly known. Inhibition of glucose transport-1 expression and also drug resistancerelated proteins such as mdr1, mrp and lrp, and increased level of proapoptotic proteins such as Bid and Bax were ever reported to form the therapeutic basis of HIF-1 interference. 34, 35 However, many factors might also limit the therapeutic efficacy of HIF-1 silencing. HIF-1a plays dual roles in the adaptive responses to hypoxia; 36,37 HIF-1 inhibition can have bimodal effects, proapoptotic or antiapoptotic, the relative dominance of which, together with environmental cues may ultimately determine the cell fate. In this study, HIF-1a silencing by lentivirusmediated HIF-1a shRNA overcame hypoxia-induced apoptosis resistance to cisplatin in fibrosarcoma cells with normal p53 status.
To gain further insight into the modulation of apoptosis pathways by both HIF-1 and p53, we next assessed the effect of HIF-1 silencing on levels of pro-and antiapoptotic proteins under hypoxic conditions. Bcl-2 level did not change occurred under hypoxia in both types of isogenic fibrosarcoma cells, which excludes the possibility of a role of Bcl-2 in apoptosis resistance. In comparison, proapoptotic proteins such as Bid might reverse the apoptosis resistance with HIF-1a knockdown. We showed Bid upregulated in fribrosarcoma cells on HIF-1 silencing, which thus conferred proapoptotic effects. Both dependence on HIF-1 and p53 might explain the changes in Bid level. Bid can be upregulated by p53 and downregulated by HIF-1.
34,38 HIF-1 silencing was then expected to potentiate the p53-induced Bid upregulation in HT1080/HIF-1a (À) cells. By contrast, mutant p53 was transcriptionally incompetent in HT1080-6TG cells, and HIF-1 silencing could increase Bid expression only slightly under hypoxia. Similarly in human colon cells, changes of Bid expression level was considered to contribute to the chemoresistance under hypoxia. 34 Bax could also be upregulated under hypoxia in both HT1080 and HT1080-6TG cells with no major difference between HIF-1-silenced cells and their parent cells. Further research is warranted to validate the findings in this study.
In summary, HIF-1a knockdown could reverse hypoxiarelated resistance to anticancer drug cisplatin only in fibrosarcoma cells with normal p53 status, and changes in expression of Bcl-2 family members under hypoxia might contribute to the differential response to HIF-1 silencing.
